A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8266 in Elderly Subjects With Hypertension.
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2014
At a glance
- Drugs MK 8266 (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Therapeutic Use
- 25 Mar 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 25 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jan 2011 Planned End Date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.